Calcium Channel Blocker Use and Risk Prostate Cancer by TMPRSS2: ERG Gene Fusion Status

Milan S. Geybels, Karen D. McCloskey, Ian G. Mills, Janet L. Stanford

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)282-290
Number of pages9
JournalProstate
Volume77
Issue number3
DOIs
Publication statusPublished - 15 Feb 2017

Keywords

  • prostate cancer
  • calcium channel blockers
  • TMPRSS2: ERG gene fusion
  • risk
  • Gleason score
  • ANTIHYPERTENSIVE DRUG-USE
  • CELL-PROLIFERATION
  • ASSOCIATION
  • HYPERTENSION
  • EXPRESSION
  • PROTEIN
  • CONSEQUENCES
  • RECEPTOR
  • CA(V)1.3

Cite this

Geybels, M. S., McCloskey, K. D., Mills, I. G., & Stanford, J. L. (2017). Calcium Channel Blocker Use and Risk Prostate Cancer by TMPRSS2: ERG Gene Fusion Status. Prostate, 77(3), 282-290. https://doi.org/10.1002/pros.23267